What we have measured.
All publicly disclosed data, with sources.
Phase 2 Clinical Trial - Stage 4 Pancreatic Cancer (mPDAC)
Median 20.3 vs 11.6 months · HR 0.58 · p=0.063 (log-rank) at the published data cutoff (March 1, 2025) · p<0.05 at the latest data recording (October 2026)
Median 15.0 vs 5.7 months · HR 0.34 · p<0.001 (log-rank)
Safety and oral administration
Robust Cancer Kill and Cancer Prevention of New Metastases
Antitumor effectiveness across multiple murine tumor models and the companion dog trial.
Bacteria collect and grow inside tumors in mouse models.
Active IL-2 produced within the tumor, in mouse models.
NK cells activated, with CD8 T cells contributing.
In 19 pet dogs with osteosarcoma treated with amputation and doxorubicin, 22% of dogs given Saltikva® were free of metastases at one year, vs under 10% of comparison dogs (Fritz et al., Vet Med Sci 2016;2(3):179–190 ↗).
In a mouse breast-cancer study, adding Saltikva® let researchers cut the chemotherapy (doxorubicin) dose by 75% and still kill as many tumor cells as the full dose.
Single Oral Dose Is Highly Effective in Treating Primary and Recurrent Disease
